Hiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses final overall survival results from the phase 3 IMpassion130 trial in triple-negative breast cancer.
Hiroji Iwata, MD, PhD
Advertisement
Articles by Hiroji Iwata, MD, PhD
Hiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses DS-8201a in HER2-positive breast cancer.
Advertisement
Latest Updated Articles
Dr. Iwata on Final OS Results From the Phase 3 IMpassion130 Trial in TNBCNovember 20th 2020
Dr. Iwata Discusses DS-8201a in HER2+ Breast CancerJuly 9th 2018
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
2
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
3
Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC
4
FDA Flashback: Breast Cancer Decisions and News From June 2026
5